Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was down 16.7% on Friday . The stock traded as low as C$0.08 and last traded at C$0.08. Approximately 405,500 shares were traded during mid-day trading, an increase of 4% from the average daily volume of 389,087 shares. The stock had previously closed at C$0.09.
Hemostemix Trading Up 6.7%
The company’s fifty day moving average is C$0.12 and its two-hundred day moving average is C$0.13. The stock has a market cap of C$11.66 million, a price-to-earnings ratio of -2.33 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Energy Stocks to Gain Exposure to the Carbon Capture Boom
- Investing in Commodities: What Are They? How to Invest in Them
- AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple
- How to Use High Beta Stocks to Maximize Your Investing Profits
- The Real Reason Ford Stock Is Rallying—Can It Keep Going?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
